Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

ATM is a target for positive regulation by E2F-1

Oncogene volume 22, pages 161–167 (2003)Cite this article

Abstract

The E2F-1 transcription factor is a critical downstream target of the tumor suppressor, RB. When activated, E2F-1 induces cell proliferation. In addition, deregulation of E2F-1 constitutes an oncogenic stress that can induce apoptosis. The protein kinase ATM is a pivotal mediator of the response to another type of stress, genotoxic stress. In response to ionizing radiation, ATM activates the tumor suppressor p53, a key player in the control of cell growth and viability. We show here that E2F-1 elevates ATM promoter activity and induces an increase in ATM mRNA and protein levels. This is accompanied by an E2F-induced increase in p53 phosphorylation. Expression of the E7 protein of HPV16, which dissociates RB/E2F complexes, also induces the elevation of ATM levels and p53 phosphorylation, implicating endogenous E2F in these phenomena. These data demonstrate that ATM is transcriptionally regulated by E2F-1 and suggest that ATM serves as a novel, ARF-independent functional link between the RB/E2F pathway and p53.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y . (1998). Science, 281, 1674–1677.

  • Berkovich E and Ginsberg D . (2001). J. Biol. Chem., 10, 42851–42856.

  • Blattner C, Sparks A and Lane D . (1999). Mol. Cell Biol., 19, 3704–3713.

  • Brown KD, Ziv Y, Sadanandan SN, Chessa L, Collins FS, Shiloh Y and Tagle DA . (1997). Proc. Natl. Acad. Sci. USA, 94, 1840–1845.

  • Byrd PJ, Cooper PR, Stankovic T, Kullar HS, Watts GD, Robinson PJ and Taylor MR . (1996). Hum. Mol. Genet., 5, 1785–1791.

  • Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB and Siliciano JD . (1998). Science, 281, 1677–1679.

  • Dyson N . (1998). Genes Dev., 12, 2245–2262.

  • Gottifredi V, Karni-Schmidt O, Shieh SS and Prives C . (2001). Mol. Cell Biol., 21, 1066–1076.

  • Hofmann F, Martelli F, Livingston DM and Wang Z . (1996). Genes Dev., 10, 2949–2959.

  • Imai T, Sugawara T, Nishiyama A, Shimada R, Ohki R, Seki N, Sagara M, Ito H, Yamauchi M and Hori T . (1997). Genomics, 42, 388–392.

  • Imai T, Yamauchi M, Seki N, Sugawara T, Saito T, Matsuda Y, Ito H, Nagase T, Nomura N and Hori T . (1996). Genome Res., 6, 439–447.

  • Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M and Nevins JR . (2001). Mol. Cell Biol., 21, 4684–4699.

  • Johnson DG, Schwarz JK, Cress WD and Nevins JR . (1993). Nature, 365, 349–352.

  • Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller SP and Lavin MF . (1998). Nat. Genet., 20, 398–400.

  • Kowalik TF, DeGregori J, Schwarz JK and Nevins JR . (1995). J. Virol., 69, 2491–2500.

  • Krek W, Livingston DM and Shirodkar S . (1993). Science, 262, 1557–1560.

  • Lin WC, Lin FT and Nevins JR . (2001). Genes Dev., 15, 1833–1844.

  • Lindeman GJ, Gaubatz S, Livingston DM and Ginsberg D . (1997). Proc. Natl. Acad. Sci. USA, 94, 5095–5100.

  • Ma T, Van Tine BA, Wei Y, Garrett MD, Nelson D, Adams PD, Wang J, Qin J, Chow LT and Harper JW . (2000). Genes Dev., 14, 2298–2313.

  • Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD and Helin K . (2001). Genes Dev., 15, 267–285.

  • Nevins JR . (1998). Cell Growth Differ., 9, 585–593.

  • O’Connor DJ and Lu X . (1999). Oncogene, 19, 2369–2376.

  • Philips AC, Bates S, Ryan KM, Helin K and Vousden KH . (1997). Genes Dev., 11, 1853–1863.

  • Polager S, Kalma Y, Berkovich E and Ginsberg D . (2002). Oncogene, 21, 437–446.

  • Qin XQ, Livingston DM, Kaelin Jr WG and Adams PD . (1994). Proc. Natl. Acad. Sci. USA, 91, 10918–10922.

  • Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA and Dynlacht BD . (2002). Genes Dev., 16, 245–256.

  • Rogoff HA, Pickering MT, Debatis ME, Jones S and Kowalik TF . (2002). Mol. Cell Biol., 22, 5308–5318.

  • Russell JL, Powers JT, Rounbehler RJ, Rogers PM, Conti CJ and Johnson DG . (2002). Mol. Cell Biol., 22, 1360–1368.

  • Sherr CJ and Weber JD . (2000). Curr. Opin. Genet. Dev., 10, 94–99.

  • Shiloh Y . (2001). Curr. Opin. Genet. Dev., 11, 71–77.

  • Tolbert D, Lu X, Yin C, Tantama M and Van Dyke T . (2002). Mol. Cell Biol., 22, 370–377.

  • Tsai KY, MacPherson D, Rubinson DA, Crowley D and Jacks T . (2002). Curr. Biol., 12, 159–163.

  • Vigo E, Muller H, Prosperini E, Hateboer G, Cartwright P, Moroni MC and Helin K . (1999). Mol. Cell Biol., 19, 6379–6395.

  • Wang A, Schneider BR, Kumar AP, MacLeod MC and Johnson DG . (2000a). J. Biol. Chem., 275, 4532–4536.

  • Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ and Qin J . (2000b). Genes Dev., 14, 927–939.

  • Watters D, Khanna KK, Beamish H, Birrell G, Spring K, Kedar P, Gatei M, Stenzel D, Hobson K, Kozlov S, Zhang N, Farrell A, Ramsay J, Gatti R and Lavin M . (1997). Oncogene, 14, 1911–1921.

  • Weinmann AS, Yan PS, Oberley MJ, Huang TH and Farnham PJ . (2002). Genes Dev., 16, 235–244.

  • Xu G, Livingston DM and Krek W . (1995). Proc. Natl. Acad. Sci. USA, 92, 1357–1361.

  • Zhao J, Kennedy BK, Lawrence BD, Barbie DA, Matera AG, Fletcher JA and Harlow E . (2000). Genes Dev., 14, 2283–2297.

  • Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ and Roussel MF . (1998). Genes Dev., 12, 2424–2433.

Download references

Acknowledgements

We thank Dr Moshe Oren for pBABE-E7 and pBABE-E7Δ (21–35) and anti-p53 antibodies, Dr Yossi Shiloh for anti-ATM antibodies, Dr Kristian Helin for pBABE-HA-ER-E2F-1 and Dr Reuven Agami for pRetroSuper-p53siRNA. We are indebted to Drs Shiloh and Oren for discussions and a critical reading of this manuscript. This study was supported by the Israel Cancer Research Fund (ICRF) and Yad Abraham Research Center for Diagnostics and Therapy. DG is an incumbent of the Recanati Career Development chair of cancer research.

Author information

Authors and Affiliations

  1. Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, 76100, Israel

    Eli Berkovich & Doron Ginsberg

Authors
  1. Eli Berkovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Doron Ginsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Doron Ginsberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berkovich, E., Ginsberg, D. ATM is a target for positive regulation by E2F-1. Oncogene 22, 161–167 (2003). https://doi.org/10.1038/sj.onc.1206144

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206144

Keywords

This article is cited by

Search

Advanced search

Quick links